Chain Drug Review - Zaditor debuts
January 22, 2007 -- Novartis Pharmaceuticals Corp. has begun marketing Zaditor, a nonprescription eye-itch treatment. Zaditor is said to offer up to 12 hours of...
Chain Drug Review - Zaditor availability
December 18, 2006 -- Zaditor, approved in 1999 as a prescription for the temporary prevention of itching of the eye caused by allergies, is expected to be in chain drug...
Optometric Management - Zaditor has multiple actions
February 1, 2000 -- CIBA Vision announces the launch of Zaditor (ketotifen fumarate ophthalmic solution, 0.025%). Zaditor is indicated for the temporary prevention of...
Chain Drug Review - Small chain niche picks
August 4, 2008 -- SMALL CHAIN NICHE PICKS *PRODUCT MANUFACTURERBayer Health Advantage Bayer HealthCareBounty Basic Paper...
Chain Drug Review - Rx to O-T-C switches fuel gains
April 7, 2008 -- NEW YORK -- Sales of eye itch/eye redness relievers, one of the leading growth segments of the eye care sector, have been driven by the late 2006...
Chain Drug Review - Alcorn Inc
August 20, 2007 -- * Alcorn Inc. It has received an FDA O.K. for a generic copy of Novartis' Zaditor eye solution. The product is known by its generic name of fumarate...
Drug Store News - Suppliers see new drivers for eye care category
September 10, 2007 -- While the lens care solution recalls from both Bausch & Lomb and Advanced Medical Optics continues to impact eye care sales, Novartis and...
Daily Herald (Arlington Heights, IL) - Local Focus.(Business)
July 28, 2007 -- Akorn announces FDA approval BUFFALO GROVE - Akorn Inc. Friday said that the U.S. Food and Drug Administration has granted approval for...
Drug Store News - OTC hot picks
July 23, 2007 -- Perhaps the most significant trend to come out of this year's National Association of Chain Drug Stores' Marketplace Conference was the number of...
Chain Drug Review - Allergy eyedrops arrive
April 9, 2007 -- NEW YORK -- Over-the-counter availability of two 12-hour allergy eyedrops is recasting the vision care category, according to Bausch & Lomb...
